{"filings":[{"id":91688,"accession_number":"0001175680-26-000002","cik":1175680,"company_name":"CytoDyn Inc.","ticker":"CYDY","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"CytoDyn holds investor call for corporate and clinical update; no material results disclosed in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company held investor call on April 30, 2026 at 1:00 p.m. PT to provide corporate and clinical update.","Presentation materials furnished as Exhibit 99.1 titled 'Leronlimab – A Novel Therapeutic in CCR5+ Immuno-Oncology'.","No specific financial or trial data included in the 8-K or exhibit; update is forward-looking without new quantitative details."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":422103232.340625,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101925,"accession_number":"0001104659-26-033943","cik":1175680,"company_name":"CytoDyn Inc.","ticker":"CYDY","form_type":"8-K","filed_at":"2026-03-24T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"CytoDyn extends $57M convertible notes maturity by 36 months, pays $1M/month in stock","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Note 1 ($28.5M) maturity extended to April 5, 2029; Note 2 ($28.5M) to April 23, 2029.","Monthly payment of $1M in common stock to noteholders priced at lower of prior close or 5-day average.","Annual interest rate on both notes reduced to 5% from prior rate as part of extension.","Total principal unchanged at $57M; company avoids immediate cash repayment through equity issuance.","Extension provides near-term liquidity relief but adds ongoing dilution for shareholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":422103232.340625,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101924,"accession_number":"0001104659-26-023856","cik":1175680,"company_name":"CytoDyn Inc.","ticker":"CYDY","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"CytoDyn raises $17.5M via private placement of 81.4M units at $0.2153 per unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Private placement of ~81.4M units (share + warrant) to accredited investors for ~$17.5M in cash.","Warrants have a 5-year term, exercise price $0.26 per share, fully exercisable at issuance.","Direct sale of 3,944,773 shares for ~$1.0M on Jan 23, 2026 (no warrants).","SEPA with Yorkville: ~0.8M shares issued for ~$0.2M in Jan 2026.","Convertible note exchanges: $1.5M principal exchanged for ~5.9M common shares in Jan/Feb 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":422103232.340625,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118261,"accession_number":"0001104659-25-117154","cik":1175680,"company_name":"CytoDyn Inc.","ticker":"CYDY","form_type":"8-K","filed_at":"2025-12-01T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"CytoDyn agrees to settle securities class action for $500K cash and 49M shares","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Settlement in principle: $500,000 cash plus 49 million shares for dismissal of all claims.","Agreement subject to final documentation, court approval, and other conditions.","No admission of fault or liability by CytoDyn; company will defend vigorously if settlement fails.","If unsettled, the securities class action could materially affect financial condition and results."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":422103232.340625,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118260,"accession_number":"0001104659-25-115056","cik":1175680,"company_name":"CytoDyn Inc.","ticker":"CYDY","form_type":"8-K","filed_at":"2025-11-21T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"CytoDyn shareholders approve increase in authorized shares to 2.25B; all directors reelected","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Authorized common stock increased from 1.75B to 2.25B shares; approved 671,591,768 For vs 69,716,006 Against.","All five director nominees elected: Tanya Urbach, Stephen Simes, Ryan Dunlap, Lishomwa Ndhlovu, Karen Brunke.","Advisory vote on executive compensation passed with 389,864,422 For, 108,351,482 Against.","Shareholders ratified CBIZ CPAs as auditor for FY ending May 31, 2026; vote 721,348,317 For.","Advisory vote on frequency of say-on-pay set at one year; 451,446,382 votes for one year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":422103232.340625,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118259,"accession_number":"0001104659-25-105306","cik":1175680,"company_name":"CytoDyn Inc.","ticker":"CYDY","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"CytoDyn secures $30M equity funding commitment from Yorkville Advisors over 36 months","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $30M in common stock sales to Yorkville over 36 months; company controls timing, no minimum draws.","Shares priced at 98% of lowest 3-day VWAP; Yorkville capped at 4.99% beneficial ownership.","Commitment fee of 1% paid in shares (half immediately, half at 6 months); structuring fee $25k.","Proceeds for working capital, debt repayment, and leronlimab PD-L1 program development.","No warrants or derivatives; registration statement to be filed for resale."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":422103232.340625,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151617,"accession_number":"0001558370-25-007954","cik":1175680,"company_name":"CytoDyn Inc.","ticker":"CYDY","form_type":"8-K","filed_at":"2025-05-16T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"CytoDyn swaps auditor from Marcum to CBIZ after Marcum resignation; no accounting disagreements","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Marcum LLP resigned as independent auditor effective May 14, 2025; CBIZ CPAs P.C. engaged same day for FY ending May 31, 2025.","Marcum's attest business was acquired by CBIZ on Nov 1, 2024; substantially all attest staff joined CBIZ.","Marcum's FY 2024 audit report had no adverse opinion but noted substantial doubt about going concern.","No disagreements or reportable events between CytoDyn and Marcum during FY 2024 and interim through resignation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":422103232.340625,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151616,"accession_number":"0001558370-25-006531","cik":1175680,"company_name":"CytoDyn Inc.","ticker":"CYDY","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"CytoDyn appoints Robert E. Hoffman as CFO effective May 15, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Hoffman replaces interim CFO Mitch Cohen; Cohen resigns effective May 12 with last day May 30.","Compensation includes $450,000 base salary, 40% target bonus, option for 1M shares, PSUs for 3.5M shares.","Hoffman has 30+ years biotech experience; previously CFO at Heron Therapeutics, AnaptysBio, and Arena Pharmaceuticals.","Hoffman currently serves on boards of Esperion Therapeutics, TuHURA Biosciences, and Fibrobiologics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":422103232.340625,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187449,"accession_number":"0001558370-24-015918","cik":1175680,"company_name":"CytoDyn Inc.","ticker":"CYDY","form_type":"8-K","filed_at":"2024-11-22T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"CytoDyn shareholders elect all director nominees at 2024 Annual Meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Tanya Durkee Urbach, Stephen M. Simes, Ryan M. Dunlap, Lishomwa C. Ndhlovu, and Karen J. Brunke elected as directors for one-year terms.","Ratification of Marcum LLP as independent auditor for fiscal year ending May 31, 2025 approved with 619.8M votes for vs 9.1M against.","Advisory vote on named executive officer compensation approved with 316.0M for, 63.2M against.","Broker non-votes of 247.7M shares for director elections and say-on-pay due to broker discretionary voting rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":422103232.340625,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203964,"accession_number":"0001558370-24-009701","cik":1175680,"company_name":"CytoDyn Inc.","ticker":"CYDY","form_type":"8-K","filed_at":"2024-07-09T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"CytoDyn settles Amarex lawsuit for $12M cash payment and $14M liability elimination","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amarex to pay CytoDyn $12 million total, with $10 million received upon execution.","Surety bond of $6.5 million released and cash collateral returned to CytoDyn.","CytoDyn's $14 million accounts payable to Amarex eliminated at no cost.","Mutual release of all claims ends litigation filed in October 2021.","CEO cites improved balance sheet and ability to advance leronlimab trials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":422103232.340625,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220618,"accession_number":"0001558370-24-009629","cik":1175680,"company_name":"CytoDyn Inc.","ticker":"CYDY","form_type":"8-K","filed_at":"2024-06-28T23:59:59+00:00","items":["4.01"],"status":"ready","headline":"CytoDyn appoints Marcum LLP as new independent auditor effective June 28","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Marcum LLP engaged as independent registered public accounting firm effective June 28, 2024.","Marcum will audit CytoDyn's fiscal year ending May 31, 2024 and review Q1-Q3 2025.","Appointment approved by Audit Committee; no prior auditor disagreements disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":422103232.340625,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220617,"accession_number":"0001558370-24-008869","cik":1175680,"company_name":"CytoDyn Inc.","ticker":"CYDY","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"CytoDyn reports unregistered sale of 52.6M units at $0.13/unit, diluting equity by >5%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["52.6M units sold in private placement; 10.1M from note conversions, plus 1.5M follow-on units.","Each unit: one common share and one warrant (exercise $0.21, 5-year term).","Placement agent received 13% cash fee and warrants to purchase ~7.9M shares (10-year term).","Follow-on offering netted ~$0.2M in proceeds.","Aggregate unregistered sales exceeded 5% of shares outstanding as of March 28, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":422103232.340625,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220616,"accession_number":"0001558370-24-006814","cik":1175680,"company_name":"CytoDyn Inc.","ticker":"CYDY","form_type":"8-K","filed_at":"2024-05-06T23:59:59+00:00","items":["4.01"],"status":"ready","headline":"CytoDyn dismisses BF Borgers as auditor after SEC permanent bar; replacement search underway","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dismissed BF Borgers on May 6, 2024, following SEC order on May 3 permanently barring the firm.","BF Borgers was engaged Oct 5, 2023 through May 3, 2024, but did not perform any audit of CytoDyn's financials.","No disagreements or reportable events existed between CytoDyn and BF Borgers during the engagement.","Audit Committee has begun search for new independent auditor for FY ending May 31, 2024; selection pending."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":422103232.340625,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220615,"accession_number":"0001558370-24-004802","cik":1175680,"company_name":"CytoDyn Inc.","ticker":"CYDY","form_type":"8-K","filed_at":"2024-04-08T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"CytoDyn restructures $43.8M Samsung debt; payment contingent on revenue","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Total balance of $43,821,231.32 restructured; only $250,000 due by Dec 31, 2024; remainder contingent on 20% of qualifying annual revenue.","Interest will not accrue on the balance during repayment period; debt is repayable only upon achieving defined 'Revenue' events.","Letter Agreement terminates Master Services Agreement from April 2019; Samsung will ship specified drug product to storage at CytoDyn’s discretion.","CytoDyn states it has sufficient drug product and substance for planned clinical activity; will transition manufacturing services to other current providers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":422103232.340625,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240240,"accession_number":"0001558370-24-004282","cik":1175680,"company_name":"CytoDyn Inc.","ticker":"CYDY","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"CytoDyn reports unregistered sales of ~20.6M shares and warrants for $3.5M; note exchange adds 10.4M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Private placement of ~20.6M units at ~$0.17/unit raised ~$3.5M; each unit = 1 share + 5-yr warrant at $0.21.","Placement agent receives 13% cash fee + warrants for 15% of shares sold (~3.1M warrants, 10-yr term).","Convertible note exchange reduced principal by $1.5M, issued ~10.4M shares to note holder in Jan-Feb 2024.","Sales triggered disclosure because aggregate unregistered sales exceeded 5% of Dec 31, 2023 outstanding shares.","Issuances exempt under Rule 506(b) (private placement) and Section 3(a)(9) (exchange)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":422103232.340625,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240239,"accession_number":"0001558370-24-000603","cik":1175680,"company_name":"CytoDyn Inc.","ticker":"CYDY","form_type":"8-K","filed_at":"2024-01-29T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"CytoDyn appoints Jacob Lalezari as permanent CEO, names Mitchell Cohen interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jacob Lalezari appointed CEO effective Jan 26, 2024; previously interim CEO since Nov 2023.","Base salary $400K, target annual bonus 40%, option grant of 3M shares vesting over 4 years.","Antonio Migliarese resigns as CFO effective Jan 31, 2024; last day Feb 15.","Mitchell Cohen appointed interim CFO effective Feb 1, 2024; independent contractor via Rapid Deployment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":422103232.340625,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257751,"accession_number":"0001558370-23-020003","cik":1175680,"company_name":"CytoDyn Inc.","ticker":"CYDY","form_type":"8-K","filed_at":"2023-12-22T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"CytoDyn settles class action over director removal clause; pays $59,500","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Class action challenged 'Only With Cause Clause' for removing directors; court invalidated it in January 2022.","Company filed Certificate of Correction in April 2022 to remove the clause per court order.","Settlement reached in December 2023: $59,500 in attorneys' fees and expenses plus $500 service award to plaintiffs.","No admission of liability; court has not expressed opinion on fee amount."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":422103232.340625,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257750,"accession_number":"0001558370-23-019804","cik":1175680,"company_name":"CytoDyn Inc.","ticker":"CYDY","form_type":"8-K","filed_at":"2023-12-14T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"CytoDyn: FDA lifts partial clinical hold, imposes new full hold on revised protocol; expects January 2024 submission","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Partial clinical hold from March 2022 lifted by FDA in December 2023.","New full clinical hold placed on proposed HIV trial protocol submitted November 2023.","Company to incorporate FDA feedback and submit amended protocol by January 2024.","Views partial hold resolution as significant step; full hold expected resolved after response.","Proposed HIV study aims to establish leronlimab's mechanism of action cost-effectively."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":422103232.340625,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257749,"accession_number":"0001558370-23-019363","cik":1175680,"company_name":"CytoDyn Inc.","ticker":"CYDY","form_type":"8-K","filed_at":"2023-11-28T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Samsung BioLogics terminates MSA with CytoDyn effective Jan 5, 2024; company has sufficient leronlimab for trials","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Samsung informed CytoDyn on Nov 21, 2023 of intent to terminate MSA effective Jan 5, 2024.","Agreement from April 2019 covered tech transfer, manufacturing, vial filling, and supply for leronlimab.","Samsung paused manufacturing for all unfulfilled commitments in January 2022.","CytoDyn states it holds sufficient leronlimab for short-term prospective clinical trials.","Company plans to continue resolving outstanding issues including breach notice, payment schedule, and extended manufacturing postponement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":422103232.340625,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257748,"accession_number":"0001558370-23-019285","cik":1175680,"company_name":"CytoDyn Inc.","ticker":"CYDY","form_type":"8-K","filed_at":"2023-11-21T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"CytoDyn appoints Jacob Lalezari as interim CEO, effective Nov 17, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Lalezari appointed interim CEO; Antonio Migliarese ceases interim President but remains CFO.","Dr. Lalezari to receive only minimum salary required by law; no cash bonus, equity, or severance.","CytoDyn has paid ~$1.5M to Lalezari's firm Quest Clinical Research since June 2021; $0.4M outstanding.","Board seeks permanent CEO; Lalezari expected to serve a few months to resolve clinical hold and pursue partnerships.","Dr. Lalezari previously served as interim CMO in 2020 and has advised the company for several years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":422103232.340625,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257747,"accession_number":"0001558370-23-018526","cik":1175680,"company_name":"CytoDyn Inc.","ticker":"CYDY","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"CytoDyn shareholders approve authorized common stock increase to 1.75B shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized shares increased from 1.35B to 1.75B, approved by 504.7M for vs 42.6M against.","All five director nominees elected: Tanya Durkee Urbach, Stephen Simes, Ryan Dunlap, Lishomwa Ndhlovu, Karen Brunke.","Advisory vote on named executive officer compensation passed with 297.5M for, 63.6M against, 14.2M abstentions.","Share increase effective immediately upon filing Certificate of Amendment with Delaware Secretary of State on Nov 9, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":422103232.340625,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257746,"accession_number":"0001558370-23-017624","cik":1175680,"company_name":"CytoDyn Inc.","ticker":"CYDY","form_type":"8-K","filed_at":"2023-11-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"CytoDyn remains under FDA clinical hold; seeks authorized share increase for viability","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA partial clinical hold still unresolved; comprehensive resubmission made, outcome pending.","Workforce reductions implemented; cash burn rate and operating expenses cut to conserve resources.","Amarex arbitration final hearing scheduled for August 12, 2024; Sidley Austin LLP retained.","Developed MASH clinical trial protocol and AI partnership for longer-acting therapeutic.","Shareholders asked to approve increase in authorized common shares at Nov 9 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":422103232.340625,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257745,"accession_number":"0001558370-23-016328","cik":1175680,"company_name":"CytoDyn Inc.","ticker":"CYDY","form_type":"8-K","filed_at":"2023-10-10T23:59:59+00:00","items":["4.01"],"status":"ready","headline":"CytoDyn appoints BF Borgers as auditor after MGO resignation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit Committee engaged BF Borgers CPA PC as independent auditor for FY ending May 31, 2024.","Appointment follows MGO's resignation as auditor, disclosed in September 25, 2023 8-K.","MGO representatives will not attend the annual meeting on November 9, 2023.","No reportable disagreements or adverse opinions were disclosed regarding the change."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":422103232.340625,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275107,"accession_number":"0001558370-23-016013","cik":1175680,"company_name":"CytoDyn Inc.","ticker":"CYDY","form_type":"8-K","filed_at":"2023-09-25T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"CytoDyn auditor MGO declines re-election for FY2024; no accounting disagreements","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["MGO declined to stand for re-election as CytoDyn's independent auditor for fiscal year 2024 on Sept 19, 2023.","MGO's audit reports for FY2022 and FY2023 contained no adverse opinion but expressed substantial going-concern doubt.","No disagreements on accounting principles or practices between CytoDyn and MGO during the two most recent fiscal years.","Material weaknesses in internal control reported for FY2022 were remediated; controls effective as of FY2023.","Audit committee is in the process of selecting a new registered public accounting firm."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":422103232.340625,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275106,"accession_number":"0001558370-23-015074","cik":1175680,"company_name":"CytoDyn Inc.","ticker":"CYDY","form_type":"8-K","filed_at":"2023-08-17T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"CytoDyn discloses unregistered equity sales raising ~$3.5M with heavy dilution","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Converted $2.0M of convertible note principal into ~9.8M shares via exchange; relied on Section 3(a)(9).","April 2023 private placement sold ~0.5M units at $0.23/unit; net proceeds ~$0.1M.","Mid-2023 offering raised ~$1.1M from 5.4M units at ~$0.20/unit; placement agent gets 12% fee plus warrants.","$2.3M placement agent notes converted into ~11.5M shares at $0.20/unit; additional ~11.5M warrants issued at $0.306/share.","Aggregate dilution from these transactions exceeds ~22M shares plus warrants; registration of resale shares committed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":422103232.340625,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275105,"accession_number":"0001558370-23-011799","cik":1175680,"company_name":"CytoDyn Inc.","ticker":"CYDY","form_type":"8-K","filed_at":"2023-07-11T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"CytoDyn CEO resigns, returns as SVP; files $100M+ claim against former CRO Amarex","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Cyrus Arman resigned as President and PEO on July 6, 2023; returns as SVP Business Operations with reduced salary of $300k.","Antonio Migliarese continues as Interim President and CFO; board has begun search for new President/CEO.","CytoDyn filed supplemental Statement of Claim against Amarex seeking damages exceeding $100M for alleged breach of CRO services.","Under new agreement, Arman forfeited RSUs/PSUs; option to purchase 1,575,557 shares vests 40% immediately, rest over 6 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":422103232.340625,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292515,"accession_number":"0001558370-23-010412","cik":1175680,"company_name":"CytoDyn Inc.","ticker":"CYDY","form_type":"8-K","filed_at":"2023-05-24T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"CytoDyn president takes medical leave; CFO assumes interim role; new CMO and advisor appointed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Cyrus Arman, President, takes medical leave; Antonio Migliarese (CFO) named interim principal executive officer.","Dr. Melissa Palmer appointed interim Chief Medical Officer; she has NASH and liver disease expertise.","Dr. Salah Kivlighn joins as clinical and strategic advisor; 30+ years industry experience including at Merck and Kite Pharma.","Company priorities: lift HIV clinical hold on leronlimab, advance NASH phase 2b trial, explore strategic opportunities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":422103232.340625,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313167,"accession_number":"0001558370-23-003170","cik":1175680,"company_name":"CytoDyn Inc.","ticker":"CYDY","form_type":"8-K","filed_at":"2023-03-08T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"CytoDyn raises $4.9M through private placement of 21.3M units at $0.23/unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proceeds of ~$4.9M from sale of ~21.3M units, each unit one share plus one warrant to purchase one share.","Warrants have 5-year term, exercise price $0.50 per share, exercisable immediately upon issuance.","Placement agent receives 12% cash fee and 10.7M warrants at $0.23 exercise price (10-year term).","Unregistered sales exceeded 5% of outstanding common stock as of Feb 28, 2023; relying on Rule 506 and Section 4(a)(2)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":422103232.340625,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313166,"accession_number":"0001558370-23-002706","cik":1175680,"company_name":"CytoDyn Inc.","ticker":"CYDY","form_type":"8-K","filed_at":"2023-03-02T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"CytoDyn reports unregistered equity sales of ~$3.7M; President invests $100K","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Private placement raised ~$3.6M from ~15.7M units at $0.23/unit; warrants exercisable at $0.50 for 5 years.","President Dr. Cyrus Arman invested $100,000 for ~434,782 units on same terms as placement.","Issued warrant to Dr. David F. Welch for 7.5M shares at $0.10 exercise price under Surety Bond Backstop.","Total unregistered sales exceeded 5% of outstanding common stock as of Feb 1, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":422103232.340625,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313165,"accession_number":"0001558370-23-000747","cik":1175680,"company_name":"CytoDyn Inc.","ticker":"CYDY","form_type":"8-K","filed_at":"2023-02-01T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"CytoDyn raises ~$7.9M in private placement; issues shares in note exchange","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exchanged $0.5M secured convertible note for 2.5M newly issued common shares on Jan 23, 2023.","Private placement of ~34.2M units at $0.23/unit; total subscriptions ~$7.9M as of Jan 31, 2023.","Each unit includes one share and one five-year warrant with $0.50 exercise price.","Down round provision triggered in Dec 2022; issued ~0.5M additional shares to warrant holders.","Placement agent receives 12% cash fee plus 10-year warrants for 15% of shares sold."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":422103232.340625,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331712,"accession_number":"0001558370-22-018797","cik":1175680,"company_name":"CytoDyn Inc.","ticker":"CYDY","form_type":"8-K","filed_at":"2022-12-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CytoDyn CMO Scott A. Kelly resigns effective immediately","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Scott A. Kelly, M.D., resigns as Chief Medical Officer of CytoDyn on December 19, 2022.","Resignation effective immediately; no reason provided in the filing.","No replacement named; search for new CMO presumably underway."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":422103232.340625,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331711,"accession_number":"0001558370-22-018520","cik":1175680,"company_name":"CytoDyn Inc.","ticker":"CYDY","form_type":"8-K","filed_at":"2022-12-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"CytoDyn elects five directors, ratifies auditor, and approves say-on-pay at 2022 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All five director nominees elected with 249M-252M votes for; broker non-votes of 191M.","Ratification of Macias Gini & O'Connell LLP as auditor passed: 434M for, 5M against, 11M abstain.","Advisory vote on named executive officer compensation approved: 215M for, 34M against, 10M abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":422103232.340625,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331710,"accession_number":"0001558370-22-018433","cik":1175680,"company_name":"CytoDyn Inc.","ticker":"CYDY","form_type":"8-K","filed_at":"2022-12-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"CytoDyn presents R&D update on December 7, 2022; no specific data disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company held an R&D Update and posted the presentation on its website.","Presentation furnished as Exhibit 99.1, but no financial or clinical milestones are included in the filing text.","Lack of detailed data prevents assessment of material developments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":422103232.340625,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331709,"accession_number":"0001558370-22-018412","cik":1175680,"company_name":"CytoDyn Inc.","ticker":"CYDY","form_type":"8-K","filed_at":"2022-12-07T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"CytoDyn extends surety bond backstop to Jan 31, 2023; issues warrants at $0.10, reduces existing warrant exercise price","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Extends Indemnitors' surety bond obligation to Jan 31, 2023; must relieve $1.5M cash collateral by Jan 5, 2023, remaining $5M by Jan 31.","Reduces exercise price of existing 30M warrants from $0.20 to $0.10 per share; issues new warrants for 7.5M shares at $0.10.","Issues second warrant for up to 7.5M shares at $0.10, amount based on how quickly cash collateral is relieved.","Completed private warrant exchange on Nov 30: four investors exercised ~1.2M $1.00 warrants for ~9.5M shares, raising ~$2.1M.","David Fairbank Welch now deemed beneficial owner of >5% of outstanding common stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":422103232.340625,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331708,"accession_number":"0001558370-22-018211","cik":1175680,"company_name":"CytoDyn Inc.","ticker":"CYDY","form_type":"8-K","filed_at":"2022-11-25T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CytoDyn CTO Nitya G. Ray resigns effective November 21, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Nitya G. Ray, Ph.D., resigned as Chief Technology Officer effective immediately on November 21, 2022.","No replacement or interim successor was announced in the 8-K filing.","The departure was by mutual agreement between Dr. Ray and the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":422103232.340625,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331707,"accession_number":"0001558370-22-015602","cik":1175680,"company_name":"CytoDyn Inc.","ticker":"CYDY","form_type":"8-K","filed_at":"2022-10-28T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"CytoDyn withdraws BLA for leronlimab in HIV-MDR citing CRO data issues","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Voluntarily withdrew pending BLA for leronlimab as HIV combination therapy; FDA approval deemed not feasible due to CRO data quality issues.","Filed claim against former CRO for breach of Master Services Agreement, seeking damages and attorney fees.","Met primary endpoint in Phase 2b/3 HIV-MDR trial; plans to publish data in peer-reviewed journal.","Will submit responses to FDA to lift clinical hold on HIV program and pursue other indications (NASH, oncology).","Company retains Fast Track designation for metastatic triple-negative breast cancer with leronlimab."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":422103232.340625,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331706,"accession_number":"0001558370-22-015082","cik":1175680,"company_name":"CytoDyn Inc.","ticker":"CYDY","form_type":"8-K","filed_at":"2022-10-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CytoDyn director Scott Kelly resigns; Stephen Simes appointed to board.","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Scott Kelly resigned as director effective Oct 13, 2022; remains CMO and Head of Business Development.","Stephen Simes appointed director same day, filling Kelly's vacancy.","Simes has 40+ years pharma experience, former CEO of BioSante and RestorGenex, director at several firms.","Simes compensated per nonemployee director policies with cash retainers and stock options.","No disclosable transactions or family relationships between Simes and other officers/directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":422103232.340625,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":349199,"accession_number":"0001558370-22-014081","cik":1175680,"company_name":"CytoDyn Inc.","ticker":"CYDY","form_type":"8-K","filed_at":"2022-08-31T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Shareholders approve increase in CytoDyn authorized shares from 1B to 1.35B","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders voted 522,967,334 for, 19,601,702 against, 1,058,601 abstentions.","Total shares outstanding and entitled to vote: 809,522,060; 546,627,637 represented at special meeting.","Amendment to Certificate of Incorporation filed with Delaware Secretary of State on August 31, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":422103232.340625,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":349198,"accession_number":"0001558370-22-014068","cik":1175680,"company_name":"CytoDyn Inc.","ticker":"CYDY","form_type":"8-K","filed_at":"2022-08-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CytoDyn appoints Ryan Dunlap as director, effective Aug 25, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ryan Dunlap appointed as director, filling vacancy from Nader Pourhassan's Jan 2022 resignation.","Expected to join the Audit Committee; Dunlap has over 25 years of finance and operations leadership.","Currently CFO at Gurobi Optimization; prior CFO at a publicly traded biotech/pharma sales company.","Compensation consistent with non-employee director policies; includes cash retainers and stock options.","No family relationships or transactions requiring disclosure under Item 404(a) of Regulation S-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":422103232.340625,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":349197,"accession_number":"0001558370-22-012454","cik":1175680,"company_name":"CytoDyn Inc.","ticker":"CYDY","form_type":"8-K","filed_at":"2022-08-05T23:59:59+00:00","items":["4.02"],"status":"ready","headline":"CytoDyn restates FY2021 and five quarterly periods; prior financials no longer reliable","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit Committee concludes FY2021 annual and five quarterly periods should not be relied upon.","Error: convertible note settlements accounted as extinguishments instead of induced conversions.","Restatement changes non-cash loss on debt settlement, APIC, accumulated deficit, and net loss.","Estimated understatement of net loss ranges from $2.6M to $24.3M across affected periods.","Material weakness in internal control over financial reporting identified for 2020-2021 periods."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":422103232.340625,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":349196,"accession_number":"0001558370-22-010928","cik":1175680,"company_name":"CytoDyn Inc.","ticker":"CYDY","form_type":"8-K","filed_at":"2022-07-25T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"CytoDyn amends surety bond backstop deal; warrant exercise price cut to $0.20, indemnity extended to Nov 15","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Warrant exercise price reduced from $0.30 to $0.20 per share for 30M shares of common stock.","Make-Whole Warrant for 15M shares becomes immediately exercisable; previously contingent on indemnitor payment.","Deadline for Indemnitors' surety bond indemnity extended from Aug 13 to Nov 15, 2022.","Registration statement filing deadline for warrant shares extended to Dec 31, 2022.","Indemnitors waive share reservation requirement until stockholder vote on 350M share increase by Oct 14, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":422103232.340625,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":349195,"accession_number":"0001558370-22-010994","cik":1175680,"company_name":"CytoDyn Inc.","ticker":"CYDY","form_type":"8-K/A","filed_at":"2022-07-25T23:59:59+00:00","items":["3.02","5.02"],"status":"ready","headline":"CytoDyn raises $21.8M in private placement of units; corrects warrant exercise price to $0.30","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised $21.8M gross via 85.4M units at $0.255/unit; each unit = one share + 0.75 warrant.","Warrants have 5-year term, exercise price corrected to $0.30 (120% of unit price).","Placement agent receives 13% cash fee, $50k expense fee, and 19.4M 10-year warrants.","Issued 43,657 shares to former executive officer for severance payment of $15,523.","Offering exempt under Rule 506/Reg D and Section 4(a)(2); resale registration planned within 90 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":422103232.340625,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366084,"accession_number":"0001558370-22-010484","cik":1175680,"company_name":"CytoDyn Inc.","ticker":"CYDY","form_type":"8-K","filed_at":"2022-06-30T23:59:59+00:00","items":["3.02","5.02"],"status":"ready","headline":"CytoDyn raises $21.8M in private placement; appoints Cyrus Arman as President","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised ~$21.8M gross via ~85.4M units at $0.255/unit; each unit = 1 share + 3/4 warrant (5-yr term).","Cyrus Arman, Ph.D. appointed President effective July 9, 2022; replaces interim President Migliarese who stays CFO.","Arman's base salary $458K, target bonus 40%, equity grants (options $750K, RSUs/PSUs $375K) subject to shareholder vote.","Placement agent receives 13% cash fee + ~19.4M warrants (10-yr) subject to shareholder approval of authorized share increase.","Issued 43,657 shares to former executive for severance obligation of $15,523."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":422103232.340625,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366083,"accession_number":"0001558370-22-009569","cik":1175680,"company_name":"CytoDyn Inc.","ticker":"CYDY","form_type":"8-K","filed_at":"2022-05-31T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"CytoDyn raises ~$8.8M in private placement of 34.6M units with warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised $8,834,500 gross from ~34.6M units (1 share + 0.75 warrant) via placement agent.","Pricing: purchase & warrant exercise price at 85% of intraday VWAP on April 29, 2022 or final close date, whichever lower.","Placement agent fee: 13% cash + 10-year warrants for 13% of shares sold + $50K expense fee.","Issued 23,651 shares to a former executive officer for $8,042 severance payment.","Exemptions relied on: Rule 506 of Reg D and Section 4(a)(2)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":422103232.340625,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366082,"accession_number":"0001193125-22-157432","cik":1175680,"company_name":"CytoDyn Inc.","ticker":"CYDY","form_type":"8-K","filed_at":"2022-05-23T23:59:59+00:00","items":["1.01","3.02","5.02"],"status":"ready","headline":"CytoDyn settles former CMO suit, grants 8.3M shares & 7M warrants; board member resigns","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Settlement with former CMO Richard Pestell resolves breach-of-contract lawsuit; CytoDyn relinquishes 8,342,000 shares and removes transfer restrictions.","Company grants Pestell three-year warrants to purchase 7,000,000 shares at $0.37 per share, plus registration rights.","Parties dismiss lawsuit and release all claims; intangible assets from ProstaGene transaction transferred to Pestell.","Board member Jordan G. Naydenov resigned effective May 17, 2022, with no reason given."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":422103232.340625,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366081,"accession_number":"0001193125-22-148819","cik":1175680,"company_name":"CytoDyn Inc.","ticker":"CYDY","form_type":"8-K","filed_at":"2022-05-12T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"CytoDyn raises ~$6.5M in unregistered equity offerings","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received subscription agreements for ~24.4M units (1 share + 3/4 warrant) from accredited investors via placement agent.","Gross proceeds of ~$6.2M from placement agent offering; price per unit set at 85% of volume-weighted avg price.","Issued 625,000 shares and 312,500 warrants to accredited investor on April 5, 2022, for $0.25M.","Warrants have 5-year term; company will file registration statement within 90 days of final closing.","Additional ~4.6M shares and ~5.5M warrants may be issuable under adjustment provisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":422103232.340625,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366080,"accession_number":"0001193125-22-142424","cik":1175680,"company_name":"CytoDyn Inc.","ticker":"CYDY","form_type":"8-K","filed_at":"2022-05-05T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"CytoDyn raises $4.8M via private placement of 17.6M units at 85% of VWAP","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 107,707 shares to former exec for $36,671 in severance satisfaction.","Received commitments for ~17.6M units (1 share + 3/4 warrant) raising $4,785,000.","Warrants: 5-year term, exercise price = 85% of intraday VWAP on pricing date.","Placement agent: 13% cash fee plus warrants for 13% of shares sold in offering.","Company to file resale registration statement within 90 days of final closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":422103232.340625,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366079,"accession_number":"0001193125-22-117768","cik":1175680,"company_name":"CytoDyn Inc.","ticker":"CYDY","form_type":"8-K","filed_at":"2022-04-25T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CytoDyn reorganizes management: Ray remains CTO, Recknor no longer executive officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Nitya G. Ray, Ph.D., no longer COO; continues as Chief Technology Officer.","Christopher P. Recknor, M.D., named Senior Director of R&D, ceases to be executive officer.","Board approved reorganization on April 19, 2022; effective immediately."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":422103232.340625,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366078,"accession_number":"0001193125-22-109507","cik":1175680,"company_name":"CytoDyn Inc.","ticker":"CYDY","form_type":"8-K","filed_at":"2022-04-19T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"CytoDyn auditor Warren Averett resigns; MGO appointed as new auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Warren Averett resigned as CytoDyn's independent auditor effective April 13, 2022; audit committee did not recommend change.","Audit committee appointed Macias Gini & O'Connell LLP (MGO) as new auditor on April 18, 2022, subject to client acceptance.","Prior audit reports for FY2020 and FY2021 included a going concern qualification; no disagreements with Warren Averett.","Material weakness in internal controls reported for Nov 30, 2021, related to errors in additional paid-in capital and non-cash interest.","Warren Averett provided letter to SEC agreeing with CytoDyn's statements in this 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":422103232.340625,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":385572,"accession_number":"0001193125-22-092023","cik":1175680,"company_name":"CytoDyn Inc.","ticker":"CYDY","form_type":"8-K","filed_at":"2022-03-31T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"CytoDyn issues 932,272 shares to two former executives for ~$0.5M severance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 932,272 shares of common stock to two former executive officers as severance payments.","Aggregate consideration approximately $0.5 million net of payroll deductions and withholding taxes.","Number of shares based on closing price on due dates; reliance on Section 4(a)(2) exemption.","Sales exceeded 1% of shares outstanding as of March 24, 2022, triggering Item 3.02 disclosure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":422103232.340625,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-03-31T23:59:59+00:00|385572"}